TY  - JOUR
AU  - Zeyen, Thomas
AU  - Paech, Daniel
AU  - Weller, Johannes
AU  - Schäfer, Niklas
AU  - Tzaridis, Theophilos
AU  - Duffy, Cathrina
AU  - Nitsch, Louisa
AU  - Schneider, Matthias
AU  - Potthoff, Anna-Laura
AU  - Steinbach, Joachim Peter
AU  - Hau, Peter
AU  - Schlegel, Uwe
AU  - Seidel, Clemens
AU  - Krex, Dietmar
AU  - Grauer, Oliver
AU  - Goldbrunner, Roland
AU  - Zeiner, Pia Susan
AU  - Tabatabai, Ghazaleh
AU  - Galldiks, Norbert
AU  - Stummer, Walter
AU  - Hattingen, Elke
AU  - Glas, Martin
AU  - Radbruch, Alexander
AU  - Herrlinger, Ulrich
AU  - Schaub, Christina
TI  - Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
JO  - Journal of neuro-oncology
VL  - 164
IS  - 3
SN  - 0167-594x
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2023-01909
SP  - 607-616
PY  - 2023
N1  - 2023 Sep;164(3):607-616
AB  - In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and pseudoprogression rates (about 10
KW  - Glioblastoma (Other)
KW  - MGMT promotor methylation (Other)
KW  - MRI (Other)
KW  - Progression (Other)
KW  - Pseudoprogression (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37728779
DO  - DOI:10.1007/s11060-023-04444-x
UR  - https://inrepo02.dkfz.de/record/282920
ER  -